KPRX – kiora pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa [Yahoo! Finance]
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study [Yahoo! Finance]
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences [Yahoo! Finance]
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting [Yahoo! Finance]
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
Form 8-K KIORA PHARMACEUTICALS For: May 10
Form 10-Q KIORA PHARMACEUTICALS For: Mar 31
Form S-8 KIORA PHARMACEUTICALS
Form 8-K KIORA PHARMACEUTICALS For: May 01
Form EFFECT KIORA PHARMACEUTICALS
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.